"We determined that the microbiome is a key contributor in determining susceptibility [to autism-like disorders], so it suggests that you could target either the maternal microbiome or this inflammatory molecule, IL-17a," said lead researcher John Lukens, PhD, of UVA's Department of Neuroscience. "You could also use this [IL-17a] as a biomarker for early diagnosis."